Cost vs safety pillar
The FDA cleared the brand-name shortage in 2025. Mass identical-copy compounding stopped. Personalized compounded GLP-1 from licensed 503A pharmacies remains legal — at roughly 1/5 the brand cash price. This guide is the honest, non-marketing answer to whether compounded is right for your situation.
Editorial grades summarizing study quality and convergence. How we grade.
| Claim | Grade | Basis |
|---|---|---|
Brand-name semaglutide and FDA-approved tirzepatide undergo FDA review for safety, purity, and efficacy before marketing Source: accessdata.fda.gov FDA new drug application + post-marketing surveillance requirement | AStrong evidence | FDA new drug application + post-marketing surveillance requirement |
Mass identical-copy compounding ended when FDA declared semaglutide + tirzepatide shortages resolved in 2025 Source: fda.gov FDA enforcement action; shortage list cleared semaglutide Feb 2025, tirzepatide Dec 2024 | AStrong evidence | FDA enforcement action; shortage list cleared semaglutide Feb 2025, tirzepatide Dec 2024 |
Personalized compounded formulations from licensed 503A pharmacies remain legal for individual patient needs Source: fda.gov FDA section 503A guidance; requires patient-specific prescription based on documented need (allergy, dose, route) | AStrong evidence | FDA section 503A guidance; requires patient-specific prescription based on documented need (allergy, dose, route) |
Compounded GLP-1 from licensed 503A pharmacies has the same active molecule as brand Manufacturer-provided USP-grade semaglutide/tirzepatide; chain-of-custody requires PCAB-accredited pharmacy | BModerate evidence | Manufacturer-provided USP-grade semaglutide/tirzepatide; chain-of-custody requires PCAB-accredited pharmacy |
Compounded GLP-1 is identical to brand-name in efficacy No head-to-head RCT; mechanism identical at molecular level but excipients, sterility process, dosing accuracy vary by pharmacy | CLimited evidence | No head-to-head RCT; mechanism identical at molecular level but excipients, sterility process, dosing accuracy vary by pharmacy |
Compounded GLP-1 from unlicensed sellers or international websites is FDA-approved Source: fda.gov Multiple FDA warning letters in 2024-2025; counterfeit pens with no active ingredient documented | FNo evidence | Multiple FDA warning letters in 2024-2025; counterfeit pens with no active ingredient documented |
Two filtered ranking pages — both vet provider legitimacy before listing.
Affiliate disclosure: we earn commissions on signups via these links. Editorial scoring is independent — see how we rank.
Licensed 503A telehealth practices that prescribe compounded semaglutide and tirzepatide. Cash-pay from $149/mo.
Compounded 503A telehealth
Henry Meds
Compounded semaglutide + tirzepatide, cash-pay $149+
Best for: Cheapest compounded 503A access
Affiliate
Compounded 503A telehealth
Mochi Health
Compounded GLP-1 + nutritionist coaching, in-network for some plans
Best for: Compounded with nutrition coaching
Direct
Compounded 503A telehealth
Eden
Compounded semaglutide + tirzepatide, simple cash-pay
Best for: Streamlined cash-pay compounded access
Direct
Compounded 503A telehealth
FuturHealth
Compounded GLP-1 + AI-assisted personalization
Best for: AI-driven cash-pay model
Direct
Editorial selection. "Direct" links go to the company’s homepage — we are not yet an affiliate partner with them and earn no commission on those signups. "Affiliate" links route through our /go redirect with commission tracking.
Yes when prescribed by a licensed clinician and dispensed by a licensed 503A pharmacy on a patient-specific basis (allergy, dose, or other documented need). Mass identical-copy compounding ended when FDA cleared the semaglutide shortage in February 2025.
Same active molecule when sourced from a USP-grade supplier. Different in: FDA oversight (compounded is not FDA-approved as a finished product), inactive ingredients, sterility process variability between pharmacies, and pricing (typically $149-300/mo vs $800-1300 brand list).
Check PCAB (Pharmacy Compounding Accreditation Board) accreditation, verify state pharmacy license, and use telehealth providers that publicly name their compounding partners. Walk away from any seller without a US pharmacy license or refusing to disclose their pharmacy.
Almost never. Compounded medications are typically cash-pay only. The cash price ($149-300/mo) is usually lower than insured copays for brand-name GLP-1 when the formulary requires high tier-3 or specialty placement.